February 13, 2020 04:53 PM EST

8 years after its OK, Eisai yanks its flailing obesity drug from the market after FDA flagged higher cancer rate

Amber Tong

CAMELLIA-TIMI 61 was supposed to be the trial that would resolve the FDA’s concerns about Belviq as Eisa investigators showed that the weight loss drug …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

8 years after its OK, Eisai yanks its flailing obesity drug from the market after FDA flagged higher cancer rate

Amber Tong

Sign up to read this article for free.

Idorsia eyes layoffs, tees up Tryvio licensing deal to extend cash runway

To lead NIH, Trump taps Stanford academic and pandemic response critic Jay Bhattacharya

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

Norbert Bischofberger's time as Kronos CEO ends as biotech seeks new life

Acadia snaps up an essential tremor drug after field's summer setbacks

Recursion reduces workforce; Oxford Nanopore teams up with UK Biobank

8 years af­ter its OK, Ei­sai yanks its flail­ing obe­si­ty drug from the mar­ket af­ter FDA flagged high­er can­cer rate

Amber Tong

Sign up to read this article for free.

more like this

Idor­sia eyes lay­offs, tees up Tryvio li­cens­ing deal to ex­tend cash run­way

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

Aca­dia snaps up an es­sen­tial tremor drug af­ter field­'s sum­mer set­backs

Re­cur­sion re­duces work­force; Ox­ford Nanopore teams up with UK Biobank

8 years after its OK, Eisai yanks its flailing obesity drug from the market after FDA flagged higher cancer rate

Idorsia eyes layoffs, tees up Tryvio licensing deal to extend cash runway

To lead NIH, Trump taps Stanford academic and pandemic response critic Jay Bhattacharya

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

Norbert Bischofberger's time as Kronos CEO ends as biotech seeks new life

Acadia snaps up an essential tremor drug after field's summer setbacks

Recursion reduces workforce; Oxford Nanopore teams up with UK Biobank